Eric D Hsi

List of Publications by Year
in descending order

283 papers	12,207 citations	31976 53 h-index	30087 103 g-index
285 all docs	285 docs citations	285 times ranked	13018 citing authors

#	Article	IF	Citations
1	Genetic and Functional Drivers of Diffuse Large BÂCell Lymphoma. Cell, 2017, 171, 481-494.e15.	28.9	804
2	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4021-4031.	1.4	596
3	The genetic landscape of mutations in Burkitt lymphoma. Nature Genetics, 2012, 44, 1321-1325.	21.4	517
4	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	1.4	512
5	Genetic heterogeneity of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1398-1403.	7.1	494
6	CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma. Clinical Cancer Research, 2008, 14, 2775-2784.	7.0	491
7	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood, 2014, 124, 1473-1480.	1.4	401
8	STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood, 2012, 120, 3048-3057.	1.4	360
9	Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 2012, 26, 2103-2113.	7.2	301
10	MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death and Disease, 2015, 6, e1593-e1593.	6.3	292
11	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 2006, 107, 4207-4213.	1.4	248
12	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, 2014, 123, 2645-2651.	1.4	192
13	Chromosomal Rearrangements of 6p25.3 Define a New Subtype of Lymphomatoid Papulosis. American Journal of Surgical Pathology, 2013, 37, 1173-1181.	3.7	182
14	Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Modern Pathology, 2011, 24, 596-605.	5.5	178
15	Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica, 2011, 96, 1121-1127.	3.5	171
16	Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1736-1739.	3.6	163
17	The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer Discovery, 2017, 7, 369-379.	9.4	163
18	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. Journal of Clinical Oncology, 2008, 26, 447-454.	1.6	159

#	Article	IF	Citations
19	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. Journal of Experimental Medicine, 2017, 214, 1371-1386.	8.5	144
20	Plasmablastic Lymphoma and Related Disorders. American Journal of Clinical Pathology, 2011, 136, 183-194.	0.7	117
21	Prevalence and Clinical Implications of Epsteinâ€“Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries. Clinical Cancer Research, 2014, 20, 2338-2349.	7.0	117
22	Clinicopathologic Reassessment of Primary Cutaneous B-Cell Lymphomas With Immunophenotypic and Molecular Genetic Characterization. American Journal of Surgical Pathology, 2000, 24, 694-702.	3.7	115
23	The whole-genome landscape of Burkitt lymphoma subtypes. Blood, 2019, 134, 1598-1607.	1.4	113
24	Angiotropic Lymphoma: An Immunophenotypically and Clinically Heterogeneous Lymphoma. Modern Pathology, 2001, 14, 1147-1156.	5.5	112
25	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2014, 27, 958-971.	5.5	112
26	Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features. Journal of Clinical Oncology, 2002, 20, 647-655.	1.6	108
27	The Ratio of FOXP3+ Regulatory T Cells to Granzyme B+ Cytotoxic T/NK Cells Predicts Prognosis in Classical Hodgkin Lymphoma and Is Independent of bcl-2 and MAL Expression. American Journal of Clinical Pathology, 2007, 128, 958-965.	0.7	106
28	Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2016, 34, 2484-2492.	1.6	106
29	The role of autologous stem cell transplantation in patients with nodal peripheral Tâ€cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer, 2019, 125, 1507-1517.	4.1	106
30	T-Lymphoblastic Leukemia/Lymphoma. American Journal of Clinical Pathology, 2015, 144, 411-422.	0.7	105
31	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology, 2016, 29, 854-864.	5.5	104
32	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. American Journal of Surgical Pathology, 2016, 40, 36-43.	3.7	103
33	Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leukemia and Lymphoma, 2008, 49, 2081-2090.	1.3	102
34	PRPF8 defects cause missplicing in myeloid malignancies. Leukemia, 2015, 29, 126-136.	7.2	102
35	Follicular programmed death 1â€positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Human Pathology, 2011, 42, 552-557.	2.0	99
36	The Clinicopathologic Spectrum of Posttransplantation Lymphoproliferative Disorders. Archives of Pathology and Laboratory Medicine, 2007, 131, 1209-1218.	2.5	99

#	Article	IF	Citations
37	Mucosa-Associated Lymphoid Tissue-Type Lymphomas Occurring in Post-Transplantation Patients. American Journal of Surgical Pathology, 2000, 24, 100.	3.7	94
38	MYD88 L265P Mutation in Lymphoid Malignancies. Cancer Research, 2018, 78, 2457-2462.	0.9	92
39	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. Blood, 2016, 128, 469-469.	1.4	79
40	Combination of ibrutinib with <scp>ABT</scp>â€199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of <scp>BTK</scp>,<scp> AKT</scp> and <scp>BCL</scp>2 pathways. British Journal of Haematology, 2015, 168, 765-768.	2.5	75
41	Detection of immunoglobulin heavy chain gene rearrangement by polymerase chain reaction in chronic active gastritis associated with Helicobacter pylori. Human Pathology, 1996, 27, 290-296.	2.0	72
42	Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica, 2012, 97, 579-585.	3.5	72
43	A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkinâ€™s lymphoma (NHL): CALGB 50803 (Alliance). Annals of Oncology, 2017, 28, 2806-2812.	1.2	72
44	Cyclin D1-negative Blastoid Mantle Cell Lymphoma Identified by SOX11 Expression. American Journal of Surgical Pathology, 2012, 36, 214-219.	3.7	65
45	Typical and Atypical Chronic Lymphocytic Leukemia Differ Clinically and Immunophenotypically. American Journal of Clinical Pathology, 2001, 116, 655-664.	0.7	62
46	Detection of Mature T-Cell Leukemias by Flow Cytometry Using Antiâ€“T-Cell Receptor VÎ²Antibodies. American Journal of Clinical Pathology, 2003, 120, 785-794.	0.7	62
47	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica, 2017, 102, 1352-1360.	3.5	62
48	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood, 2020, 135, 2224-2234.	1.4	62
49	Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia, 2021, 35, 1023-1036.	7.2	62
50	Expression of bcl-2 in Classical Hodgkin's Lymphoma: An Independent Predictor of Poor Outcome. Journal of Clinical Oncology, 2005, 23, 3773-3779.	1.6	61
51	Acquired resistance to venetoclax (ABT-199) int(14;18)positive lymphoma cells. Oncotarget, 2016, 7, 70000-70010.	1.8	59
52	Serious pulmonary toxicity in patients with Hodgkinâ€™s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcÎ³RIIIa-158 V/F polymorphism. Annals of Oncology, 2010, 21, 2246-2254.	1.2	56
53	CLT030, a leukemic stem cellâ€“targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Advances, 2018, 2, 1738-1749.	5.2	56
54	A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia, 2020, 34, 1646-1657.	7.2	54

#	Article	IF	Citations
55	Angioimmunoblastic T-cell Lymphomas With the RHOA p.Gly17Val Mutation Have Classic Clinical and Pathologic Features. American Journal of Surgical Pathology, 2016, 40, 335-341.	3.7	53
56	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 chronic myelomonocytic leukemia. Modern Pathology, 2017, 30, 1213-1222.	5.5	52
57	A prospective cohort study of patients with peripheral Tâ€cell lymphoma in the United States. Cancer, 2017, 123, 1174-1183.	4.1	51
58	Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death and Disease, 2019, 10, 924.	6.3	51
59	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Modern Pathology, 2019, 32, 490-498.	5.5	50
60	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood, 2021, 137, 3685-3689.	1.4	50
61	Bcl-6 Protein Expression by Follicle Center Lymphomas: A Marker for Differentiating Follicle Center Lymphomas From Other Low-Grade Lymphoproliferative Disorders. American Journal of Clinical Pathology, 1999, 112, 101-107.	0.7	47
62	Evaluation of a new paraffin-reactive CD7 T-cell deletion marker and a polymerase chain reaction-based T-cell receptor gene rearrangement assay: Implications for diagnosis of mycosis fungoides in community clinical practice. Journal of the American Academy of Dermatology, 2001, 45, 405-413.	1.2	47
63	A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer, 2013, 119, 3797-3804.	4.1	47
64	Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. Haematologica, 2020, 105, 1895-1906.	3.5	46
65	A Practical Approach for Evaluating New Antibodies in the Clinical Immunohistochemistry Laboratory. Archives of Pathology and Laboratory Medicine, 2001, 125, 289-294.	2.5	46
66	Primary Cutaneous Diffuse Large B-Cell Lymphoma. American Journal of Clinical Pathology, 2002, 117, 574-580.	0.7	44
67	MAL Is Expressed in a Subset of Hodgkin Lymphoma and Identifies a Population of Patients With Poor Prognosis. American Journal of Clinical Pathology, 2006, 125, 776-782.	0.7	44
68	Biologic predictors in follicular lymphoma: Importance of markers of immune response. Leukemia and Lymphoma, 2007, 48, 2403-2411.	1.3	44
69	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas. American Journal of Surgical Pathology, 2014, 38, 768-775.	3.7	44
70	Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. British Journal of Haematology, 2003, 120, 1017-1025.	2.5	42
71	Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Annals of Oncology, 2010, 21, 1196-1202.	1.2	42
72	Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. Cancer Discovery, 2020, 10, 1267-1281.	9.4	40

#	Article	IF	Citations
73	Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: A gene expression profiling study with implications for potential combination therapies. Leukemia Research, 2008, 32, 275-285.	0.8	39
74	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2017, 187, 1700-1716.	3.8	39
75	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Modern Pathology, 2019, 32, 741-754.	5.5	39
76	Usefulness of an immunohistochemical panel in paraffin-embedded tissues for the differentiation of B-cell non-Hodgkin's lymphomas of small lymphocytes. Modern Pathology, 1998, 11, 1046-51.	5.5	38
77	Follicular Lymphoma with Marginal Zone Differentiation: Microdissection Demonstrates the t(14;18) in Both the Follicular and Marginal Zone Components. Modern Pathology, 2001, 14, 191-196.	5.5	37
78	Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment. Leukemia and Lymphoma, 2008, 49, 1668-1680.	1.3	37
79	Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response. Journal of the National Cancer Institute, 2016, 108, djw131.	6.3	37
80	Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Research, 2020, 80, 2031-2044.	0.9	36
81	Dermatofibroma and dermatofibrosarcoma protuberans: an immunohistochemical study reveals distinctive antigenic profiles. Journal of Dermatological Science, 1996, 11, 1-9.	1.9	35
82	Lymphoma Immunophenotyping: A New Era in Paraffin-Section Immunohistochemistry. Advances in Anatomic Pathology, 2001, 8, 218-239.	4.3	35
83	Myeloproliferative neoplasms with concurrent BCRâ€“ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Modern Pathology, 2018, 31, 690-704.	5.5	35
84	GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. Journal of Clinical Investigation, 2017, 127, 3527-3542.	8.2	35
85	Usefulness of CD79b Expression in the Diagnosis of B-Cell Chronic Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2000, 113, 805-813.	0.7	34
86	Indolent mantle cell lymphoma. Leukemia and Lymphoma, 2014, 55, 761-767.	1.3	33
87	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. Oncotarget, 2015, 6, 13933-13945.	1.8	33
88	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the lateral ventricle. Leukemia and Lymphoma, 2005, 46, 1423-1427.	1.3	32
89	Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma. Leukemia, 2015, 29, 1857-1867.	7.2	32
90	Use of Novel t(11;14) and t(14;18) Dual-Fusion Fluorescence In Situ Hybridization Probes in the Differential Diagnosis of Lymphomas of Small Lymphocytes. Diagnostic Molecular Pathology, 2001, 10, 214-222.	2.1	32

#	Article	IF	Citations
91	Primary cutaneous lymphoblastic lymphoma presenting in an 8-week old infant. Journal of Cutaneous Pathology, 2002, 29, 107-112.	1.3	30
92	PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin. Haematologica, 2014, 99, e148-e151.	3.5	29
93	Multiparameter Immunohistochemical Analysis of the Cell Cycle Proteins Cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in Mantle Cell Lymphoma. Archives of Pathology and Laboratory Medicine, 2000, 124, 1457-1462.	2.5	29
94	Biclonal Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2000, 113, 798-804.	0.7	28
95	The phosphatidylinositol 3â€kinases (<scp>PI</scp>3<scp>K</scp>) inhibitor <scp>GS</scp>â€1101 synergistically potentiates histone deacetylase inhibitorâ€induced proliferation inhibition and apoptosis through the inactivation of <scp>PI</scp>3<scp>K</scp> and extracellular signalâ€regulated kinase pathways. British Journal of Haematology, 2013, 163, 72-80.	2.5	28
96	Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 193-200.	0.4	27
97	Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leukemia Research, 2004, 28, 845-850.	0.8	26
98	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget, 2016, 7, 18036-18049.	1.8	26
99	Clinical approach to diffuse large B cell lymphoma. Blood Reviews, 2016, 30, 477-491.	5.7	26
100	Comparison of therapyâ€related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. American Journal of Hematology, 2020, 95, 799-808.	4.1	26
101	A Clinicopathologic Evaluation of Follicular Lymphoma Grade 3A Versus Grade 3B Reveals No Survival Differences. Archives of Pathology and Laboratory Medicine, 2004, 128, 863-868.	2.5	26
102	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Modern Pathology, 2019, 32, 1373-1385.	5.5	25
103	Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. Blood, 2015, 126, 337-337.	1.4	23
104	Nonâ€mycosis fungoides cutaneous Tâ€cell lymphoma: reclassification according to the WHOâ€EORTC classification. Journal of Cutaneous Pathology, 2010, 37, 516-524.	1.3	22
105	JAK2 V617Fâ€positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. British Journal of Haematology, 2018, 182, 78-85.	2.5	22
106	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Advances, 2020, 4, 3391-3404.	5.2	22
107	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2022, 28, 972-983.	7.0	22
108	Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leukemia and Lymphoma, 2009, 50, 2005-2012.	1.3	21

#	Article	IF	Citations
109	Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. International Journal of Laboratory Hematology, 2020, 42, 418-422.	1.3	21
110	Myeloid/lymphoid neoplasms with FLT3 rearrangement. Modern Pathology, 2021, 34, 1673-1685.	5.5	21
111	Development of extrasalivary gland lymphoma in myoepithelial sialadenitis. Modern Pathology, 1995, 8, 817-24.	5.5	20
112	Quantitative In Situ Detection of Phosphoproteins in Fixed Tissues Using Quantum Dot Technology. Journal of Histochemistry and Cytochemistry, 2009, 57, 701-708.	2.5	19
113	Characterization of DLBCL with a PMBL gene expression signature. Blood, 2021, 138, 136-148.	1.4	19
114	Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. Nature Communications, 2019, 10, 5061.	12.8	18
115	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <scp>CALGB</scp>/Alliance 50403. American Journal of Hematology, 2020, 95, 583-593.	4.1	18
116	Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma. Blood, 2013, 122, 842-842.	1.4	18
117	CCMCL1: a new model of aggressive mantle cell lymphoma. Blood, 2015, 125, 2730-2732.	1.4	17
118	CAL2 Immunohistochemical Staining Accurately IdentifiesCALRMutations in Myeloproliferative Neoplasms. American Journal of Clinical Pathology, 2016, 146, 431-438.	0.7	17
119	MAL Is Expressed in a Subset of Hodgkin Lymphoma and Identifies a Population of Patients With Poor Prognosis. American Journal of Clinical Pathology, 2006, 125, 776-782.	0.7	17
120	Molecular subtype classification of formalinâ€fixed, paraffinâ€embedded diffuse large Bâ€cell lymphoma samples on the <scp>ICEP</scp>lex^{Â®} system. British Journal of Haematology, 2014, 167, 281-285.	2.5	16
121	2016 WHO Classification updateâ€"What's new in lymphoid neoplasms. International Journal of Laboratory Hematology, 2017, 39, 14-22.	1.3	16
122	Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Modern Pathology, 2022, 35, 306-318.	5.5	16
123	Detection of Clonal IGH Gene Rearrangements: Summary of Molecular Oncology Surveys of the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2007, 131, 185-189.	2.5	16
124	NF-ÎºB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Modern Pathology, 2017, 30, 854-876.	5.5	15
125	Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 797-803.	0.4	15
126	Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. Blood Advances, 2019, 3, 132-135.	5.2	15

#	Article	IF	Citations
127	Pathology of Primary Cutaneous B-Cell Lymphomas: Diagnosis and Classification. Clinical Lymphoma and Myeloma, 2004, 5, 89-97.	2.1	14
128	Pathologic and Molecular Genetic Features of Chronic Lymphocytic Leukemia. Seminars in Oncology, 2012, 39, 74-79.	2.2	14
129	Detection of bcl-2/JH Translocation by Polymerase Chain Reaction. Archives of Pathology and Laboratory Medicine, 2002, 126, 902-908.	2.5	14
130	HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 914-923.	4.9	13
131	Ocular/adnexal lymphoma: dissimilar to systemic lymphoma. Survey of Ophthalmology, 2018, 63, 381-388.	4.0	13
132	Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. American Journal of Surgical Pathology, 2020, 44, e1-e14.	3.7	13
133	T-cell Lymphomas. Surgical Pathology Clinics, 2016, 9, 131-141.	1.7	12
134	Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 1640-1648.	1.3	12
135	Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34). International Journal of Laboratory Hematology, 2017, 39, 409-417.	1.3	12
136	CD30 Immunohistochemical Expression In Diffuse Large B-Cell Lymphoma Is Associated With Decreased Overall Survival and The Non-Germinal Center Molecular Subtype. Blood, 2013, 122, 4318-4318.	1.4	12
137	Flow Cytometric Analysis of Cerebrospinal Fluid Has Low Diagnostic Yield in Samples Without Atypical Morphology or Prior History of Hematologic Malignancy. American Journal of Clinical Pathology, 2014, 141, 515-521.	0.7	11
138	Extranodal Marginal Zone Lymphoma of the Central Nervous System Includes Parenchymal-Based Cases With Characteristic Features. American Journal of Clinical Pathology, 2020, 154, 124-132.	0.7	11
139	Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology, 2022, 35, 1411-1422.	5.5	11
140	The Leukemias of Mature Lymphocytes. Hematology/Oncology Clinics of North America, 2009, 23, 843-871.	2.2	10
141	Pathology of B-Cell Lymphomas: Diagnosis and Biomarker Discovery. Cancer Treatment and Research, 2015, 165, 27-50.	0.5	10
142	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with highâ€risk follicular lymphoma: CALGB 50904 (Alliance). Cancer, 2019, 125, 3378-3389.	4.1	10
143	Large B-cell lymphoma of the uvea: Histopathologic variants and clinicopathologic correlation. Survey of Ophthalmology, 2020, 65, 361-370.	4.0	10
144	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Antiâ€“CD20-based Biological Therapy. American Journal of Surgical Pathology, 2021, 45, 384-393.	3.7	10

#	Article	IF	Citations
145	Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20). Blood, 2010, 116, 427-427.	1.4	10
146	Immunohistochemical Analysis of CD30-Positive Lymphoproliferative Disorders for Expression of CD95 and CD95L. Modern Pathology, 2000, 13, 446-451.	5.5	9
147	SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. British Journal of Haematology, 2019, 185, 145-147.	2.5	9
148	Composite chronic myeloid leukemia and essential thrombocythemia with BCRâ€ABL1 fusion and CALR mutation. American Journal of Hematology, 2019, 94, 504-505.	4.1	9
149	Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas. American Journal of Clinical Pathology, 2020, 153, 646-655.	0.7	9
150	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology, 2021, 34, 20-31.	5.5	9
151	Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry. Blood, 2012, 120, 4263-4263.	1.4	9
152	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	5.5	9
153	Paroxysmal Nocturnal Hemoglobinuria Testing by Flow Cytometry. American Journal of Clinical Pathology, 2000, 114, 798-806.	0.7	8
154	Frequency, interobserver reproducibility and clinical significance of equivocal peaks in PCR clonality testing using Euroclonality/BIOMED-2 primers. Journal of Clinical Pathology, 2014, 67, 1093-1098.	2.0	8
155	American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. Annals of Diagnostic Pathology, 2020, 49, 151623.	1.3	8
156	Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy. Blood, 2013, 122, 3029-3029.	1.4	8
157	MAL Is Expressed in a Subset of Hodgkin Lymphomas and Identifies a Population of Patients with Poor Prognosis.. Blood, 2004, 104, 3117-3117.	1.4	8
158	Increased Tumor Infiltrating FOXP3+ Regulatory T-Cells Are Associated with Improved Survival in Classical Hodgkin Lymphoma.. Blood, 2006, 108, 2265-2265.	1.4	8
159	Phosphoproteins and the Dawn of Functional Phenotyping. Pathobiology, 2011, 78, 115-121.	3.8	7
160	Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment. Blood, 2012, 120, 1614-1614.	1.4	7
161	Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Leukemia and Lymphoma, 2016, 57, 212-215.	1.3	6
162	Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22). American Journal of Clinical Pathology, 2017, 147, 411-419.	0.7	6

#	Article	IF	Citations
163	Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. Blood, 2018, 132, 929-929.	1.4	6
164	Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study. Blood, 2018, 132, 397-397.	1.4	6
165	Prognostic Value of Tumor-Infiltrating TIA-1+ Cytotoxic T Cells (TIA1-CTCs) and FOXP3+ Regulatory T Cells (Tregs) in Post-Transplant Lymphoproliferative Disorder (PTLD) Following Solid Organ Transplant (SOT).. Blood, 2007, 110, 54-54.	1.4	6
166	CLL-1, a Receptor Expressed on Myeloid Leukemic Stem Cells, Is a Potential Target for Immunotherapy of AML. Blood, 2008, 112, 4003-4003.	1.4	6
167	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. Blood, 2012, 120, 1545-1545.	1.4	6
168	Advances in the Diagnosis and Classification of Chronic Lymphoproliferative Disorders. , 2004, 121, 145-165.		5
169	Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Human Pathology, 2016, 52, 173-178.	2.0	5
170	<scp>JAK</scp>2 double minutes with resultant simultaneous amplification of <scp>JAK</scp>2 and <scp>CD</scp>274 in a therapyâ€related myelodysplastic syndrome evolving into an acute myeloid leukaemia. British Journal of Haematology, 2019, 185, 566-570.	2.5	5
171	Immune Escape Mechanisms in Intravascular Large B-Cell Lymphoma: A Molecular Cytogenetic and Immunohistochemical Study. American Journal of Clinical Pathology, 2022, 157, 578-585.	0.7	5
172	Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization. Archives of Pathology and Laboratory Medicine, 2022, 146, 351-359.	2.5	5
173	CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.. Blood, 2006, 108, 3457-3457.	1.4	5
174	Towards a Molecular Classification of Hematolymphoid Neoplasms: Where Are We Now? Where Are We Going?. Journal of Histochemistry and Cytochemistry, 2001, 49, 1323-1324.	2.5	4
175	T-cell lymphoma in the head and neck? Think about adult T-cell leukemia/lymphoma. Leukemia and Lymphoma, 2009, 50, 150-151.	1.3	4
176	Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant. Therapeutic Advances in Hematology, 2018, 9, 81-87.	2.5	4
177	A Tissue Counterpart to Monoclonal B-Cell Lymphocytosis. Archives of Pathology and Laboratory Medicine, 2021, 145, 1544-1551.	2.5	4
178	FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R].. Blood, 2008, 112, 1003-1003.	1.4	4
179	Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2. Blood, 2010, 116, 611-611.	1.4	4
180	Cell of Origin Determination in Diffuse Large B-Cell Lymphoma: Performance of Immunohistochemical (IHC) Algorithms and Ability to Predict Outcome. Blood, 2011, 118, 950-950.	1.4	4

#	Article	IF	Citations
181	Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups. Blood, 2016, 128, 1087-1087.	1.4	4
182	Impact of next generation sequencing results on clinical management in patients with hematological disorders. Leukemia and Lymphoma, 2021, 62, 1702-1710.	1.3	4
183	Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. Blood, 2019, 134, 19-19.	1.4	4
184	The SOX11-PDGFA axis in mantle cell lymphoma. Blood, 2014, 124, 2165-2166.	1.4	3
185	Update in large cell lymphoma: understanding the pathology report. Hematology American Society of Hematology Education Program, 2015, 2015, 605-617.	2.5	3
186	Orbital diffuse large B-cell lymphoma with combined variable immunodeficiency. Orbit, 2017, 36, 340-343.	0.8	3
187	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. Modern Pathology, 2018, 31, 873-880.	5.5	3
188	Chronic active Epsteinâ€Barr virus infection: A heterogeneous entity requiring a high index of suspicion for diagnosis. International Journal of Laboratory Hematology, 2020, 42, 99-106.	1.3	3
189	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2011, 118, 949-949.	1.4	3
190	Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics. Blood, 2012, 120, 1696-1696.	1.4	3
191	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 641-641.	1.4	3
192	Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial. Blood, 2014, 124, 978-978.	1.4	3
193	Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance). Blood, 2015, 126, 2741-2741.	1.4	3
194	Hematogones Contained in CD34+ Apheresis Products for Hematopoietic Progenitor Cell Transplantation Have No Adverse Impact On Engraftment Outcomes.. Blood, 2012, 120, 3022-3022.	1.4	3
195	Update in the pathologic features of mature B-cell and T/NK-cell leukemias. Seminars in Diagnostic Pathology, 2003, 20, 180-195.	1.5	2
196	Myeloid Neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Surgical Pathology Clinics, 2013, 6, 677-692.	1.7	2
197	Lymphomas of the Gastrointestinal Tract. Surgical Pathology Clinics, 2013, 6, 405-424.	1.7	2
198	IgG4+ Plasma Cells in Isolated Reactive Lymphadenopathy. American Journal of Clinical Pathology, 2014, 142, 432-434.	0.7	2

#	Article	IF	Citations
199	Flow cytometry in cerebrospinal fluidâ€"Rational use of laboratory services. American Journal of Hematology, 2014, 89, 941-942.	4.1	2
200	General Biomarker Recommendations for Lymphoma. Journal of the National Cancer Institute, 2016, 108, djw250.	6.3	2
201	Assessment of semiâ€quantitative grading of red blood cell abnormalities utilizing images from the CellaVision <scp>DM</scp>96 compared to manual light microscopy. International Journal of Laboratory Hematology, 2017, 39, e110-e112.	1.3	2
202	Inhibition of cyclinâ€dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma. EJHaem, 2020, 1, 161-169.	1.0	2
203	Decreased BIM expression in BCL2-negative follicular lymphoma: a potential mechanism for resistance to apoptosis. Human Pathology, 2021, 107, 1-8.	2.0	2
204	Proteomic characterisations of ulcerative colitis endoscopic biopsies associate with clinically relevant histological measurements of disease severity. Journal of Clinical Pathology, 2022, 75, 636-642.	2.0	2
205	Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. Blood, 2018, 132, 2927-2927.	1.4	2
206	Phospho-IkappaB Is Abnormally Expressed in Bone Marrow of CMML Patients.. Blood, 2007, 110, 2450-2450.	1.4	2
207	Combination Of Ibrutinib With ABT-199, a BCL-2 Pathway Inhibitor: Effective Therapeutic Strategy In a Novel Mantle Cell Lymphoma Cell Line Model. Blood, 2013, 122, 645-645.	1.4	2
208	Histone H4 Acetylation as a Prognostic Factor for Patients with Acute Lymphocytic Leukemia in First Relapse.. Blood, 2008, 112, 1482-1482.	1.4	2
209	Are Mast Cells a Biologic Predictor of Outcome in Follicular Lymphoma?. Blood, 2008, 112, 3772-3772.	1.4	2
210	CBL, CBLB, TET2, ASXL1, and IDH1/2 Mutations as Well as Additional Chromosomal Aberrations Constitute Molecular Events Contributing to Malignant Progression In Advanced Philadelphia Chromosome-Positive Disorders.. Blood, 2010, 116, 3396-3396.	1.4	2
211	The Role of Biomarkers in the Management of Patients with Lymphoma: Promise Versus Reality. Clinical Lymphoma and Myeloma, 2009, 9, 121-123.	1.4	1
212	Endobronchial pseudocarcinomatous hyperplasia mimicking squamous cell carcinoma associated with primary pulmonary ALKâ€negative anaplastic large cell lymphoma. Histopathology, 2020, 76, 781-784.	2.9	1
213	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia and Lymphoma, 2020, 61, 2442-2447.	1.3	1
214	Diffuse Aggressive B-Cell Lymphomas. , 2012, , 261-292.		1
215	Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2018, 132, 1692-1692.	1.4	1
216	MYC and BCL2 mRNA Expression As Determined By NGS Predicts Survival in DLBCL in GCB but Not in ABC Subgroup. Blood, 2019, 134, 5092-5092.	1.4	1

#	Article	IF	Citations
217	Frequent Detection of C-Cbl Homozygous Mutation in Secondary Myelogeneous Leukemia Transformed from MDS/MPD with Chromosome 11q Uniparental Disomy. Blood, 2008, 112, 851-851.	1.4	1
218	CD37 Is a Potential Therapeutic Target for B-Cell Non-Hodgkin Lymphoma. Blood, 2010, 116, 3098-3098.	1.4	1
219	Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 544-544.	1.4	1
220	Molecular Characterization Of Myeloid Neoplasms Harboring Isochromosome 17q Abnormality. Blood, 2013, 122, 2596-2596.	1.4	1
221	PRPF8 Defects Cause Missplicing In Myeloid Malignancies. Blood, 2013, 122, 2838-2838.	1.4	1
222	Presence of JAK2 Mutations in MDS/MPD-u WHO Classified Patients and Not Other Forms of MDS Suggests Their Derivation from Classical Myeloproliferative Syndrome.. Blood, 2005, 106, 369-369.	1.4	1
223	The Lymphoid Cell Surface Receptor NTB-A: A Novel Monoclonal Antibody Target for Leukemia and Lymphoma Therapeutics.. Blood, 2007, 110, 4511-4511.	1.4	1
224	B-Cell Leukemias of Mature Lymphocytes. , 2012, , 387-402.		1
225	Phase II Study of Enzastaurin in Patients with Follicular Lymphoma: Updated Final Clinical Results and Immunohistochemical Correlations. Blood, 2012, 120, 777-777.	1.4	1
226	A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2012, 120, 3595-3595.	1.4	1
227	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 365-365.	1.4	1
228	Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma. Blood, 2014, 124, 864-864.	1.4	1
229	Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning. Blood, 2019, 134, 2891-2891.	1.4	1
230	Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 1499-1499.	1.4	1
231	Gene Expression and Epigenetic Analysis in Relapsed/Refractory Diffuse Large B Cell Lymphoma Provides Insights into Evolution of Treatment Resistance to R-CHOP. Blood, 2020, 136, 26-26.	1.4	1
232	Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives of Pathology and Laboratory Medicine, 2023, 147, 79-86.	2.5	1
233	Microenvironment in peripheral T cell lymphomas: macrophages and angiogenesis as targets. Leukemia and Lymphoma, 2011, 52, 3-4.	1.3	0
234	Selection and Validation of Antibodies for Signal Transduction Immunohistochemistry. Methods in Molecular Biology, 2011, 717, 45-53.	0.9	0

#	Article	IF	Citations
235	Diffuse Aggressive B-Cell Lymphomas. , 2018, , 271-305.e5.		0
236	Intensive immunochemotherapy for high-risk aggressive B-cell lymphomas: MYC-rearrangements and beyond. Lancet Haematology,the, 2018, 5, e600-e601.	4.6	0
237	Cyclin D1 Immunohistochemistry Identifies a Subset of Plasma Cell Myeloma with Superior Overall Survival.. Blood, 2004, 104, 4854-4854.	1.4	0
238	Immunohistochemical Expression of CD10, BCL6, and MUM1 in Primary Nodal Diffuse Large B-Cell Lymphoma: MUM1 Expression Alone (but Not Germinal Center B-Cell Immunophenotype) Is an Independent Prognostic Factor.. Blood, 2005, 106, 4706-4706.	1.4	0
239	Expression of NTB-A in Normal Tissue, Non-Hodgkin Lymphomas and Investigation of Its Potential Therapeutic Impact for Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 4741-4741.	1.4	0
240	Blasts Express Phospho-Akt in the Majority of Adult Patients with Acute Lymphocytic Leukemia (ALL).. Blood, 2006, 108, 1846-1846.	1.4	0
241	Histone H4 Acetylation Is Associated with Improved Relapse-Free Survival in Newly Diagnosed Patients with Acute Lymphoblastic Leukemia (ALL) Less Than 60 Years of Age without Poor Risk Cytogenetics.. Blood, 2007, 110, 2798-2798.	1.4	0
242	CLL-1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia.. Blood, 2007, 110, 2839-2839.	1.4	0
243	Dysregulated Signaling Networks in Chronic Myeloproliferative Disorders: Co-Operation of JAK2 and Src Family Kinases (SFK). Blood, 2007, 110, 1539-1539.	1.4	0
244	IREM-1 Is a Cell Surface Receptor Expressed in AML Blasts: Potential for Targeted Immunotherapy in AML.. Blood, 2007, 110, 1792-1792.	1.4	0
245	The Myeloid Cell Surface Receptor IREM-1: A Novel Monoclonal Antibody Target for Acute Myeloid Leukemia (AML). Blood, 2008, 112, 2933-2933.	1.4	0
246	Potent Anti-Cancer Activity of Anti-NTB-a Monoclonal Antibodies in Preclinical Leukemia and Lymphoma Models. Blood, 2008, 112, 4975-4975.	1.4	0
247	OCT-2 Expression and OCT-2/BOB.1 Co-Expression Predict Prognosis in Patients with Newly Diagnosed Acute Myelogenous Leukemia.. Blood, 2008, 112, 1486-1486.	1.4	0
248	Acquired 1p Uniparental Disomy Is Associated with Biallelic MPL W515L Mutation in RARS-T.. Blood, 2008, 112, 1643-1643.	1.4	0
249	CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63).. Blood, 2008, 112, 1779-1779.	1.4	0
250	A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.. Blood, 2008, 112, 955-955.	1.4	0
251	Distinct Role of Src Family Kinase Inhibitors in Burkitt Lymphoma Cells Vs. Diffuse Large B-Cell Lymphoma Cells. Blood, 2008, 112, 3765-3765.	1.4	0
252	TET2 Mutations Are Frequent in RARS-T.. Blood, 2009, 114, 3794-3794.	1.4	0

#	Article	IF	Citations
253	Strong Histone (H4) Acetylation Is Independently Associated with Better Overall Survival in Newly Diagnosed Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 4681-4681.	1.4	0
254	Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma. Blood, 2010, 116, 803-803.	1.4	0
255	Single Nucleotide Polymorphism Array (SNP-A) Genomic Profiling of Mantle Cell Lymphoma (MCL) Against a Large Control Database Reveals Recurring Copy Number Alterations (CNAs) and Copy Neutral Loss of Heterozygosity (CN-LOH). Blood, 2010, 116, 2001-2001.	1.4	0
256	Clonotype Switching Indicates Propensity for Clonal Outgrowth From Diverse Components of the T Cell Repertoire In T Cell Large Granular Lymphocyte Leukemia.. Blood, 2010, 116, 1171-1171.	1.4	0
257	Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia.. Blood, 2010, 116, 1675-1675.	1.4	0
258	Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics. Blood, 2010, 116, 2736-2736.	1.4	0
259	Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma. Blood, 2011, 118, 433-433.	1.4	0
260	A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine,. Blood, 2011, 118, 3830-3830.	1.4	0
261	Phospho-SFKs (Y416) As a Potential Predictive Marker for Dasatinib Therapy in B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia,. Blood, 2011, 118, 3727-3727.	1.4	0
262	The Impact of Molecular Lesions in Post-Transplant Acute Myeloid Leukemia (AML) in Correlation with Cytogenetic Abnormalities,. Blood, 2011, 118, 4137-4137.	1.4	0
263	A Prospective, Randomized, Chemoprevention Trial of Celecoxib for High Risk Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma. Blood, 2012, 120, 5045-5045.	1.4	0
264	Molecular Subtype Characterization of Formalin-Fixed, Paraffin-Embedded Diffuse Large B-Cell Lymphoma Samples on the IceplexÂ® System.. Blood, 2012, 120, 2705-2705.	1.4	0
265	Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. Blood, 2012, 120, 3847-3847.	1.4	0
266	BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance). Blood, 2012, 120, 301-301.	1.4	0
267	ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom. Blood, 2012, 120, 898-898.	1.4	0
268	The Genetic Landscape Of Mantle Cell Lymphoma and The Epigenetic Origins Of Lineage Specific Mutations. Blood, 2013, 122, 347-347.	1.4	0
269	MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 363-363.	1.4	0
270	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 213-213.	1.4	0

#	Article	IF	Citations
271	CNS Lymphoma. , 2014, , 207-223.		0
272	Mantle Cell Lymphoma. , 2014, , 277-302.		0
273	B-Cell Leukemias of Mature Lymphocytes. , 2018, , 397-413.e2.		0
274	TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer. Blood, 2018, 132, 2270-2270.	1.4	0
275	Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. Blood, 2018, 132, 2878-2878.	1.4	0
276	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. Blood, 2018, 132, 1491-1491.	1.4	0
277	Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab. Blood, 2019, 134, 1515-1515.	1.4	0
278	Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations. Blood, 2019, 134, 1572-1572.	1.4	0
279	Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma. Blood, 2021, 138, 2398-2398.	1.4	0
280	Integrative DNA Methylation and Gene Expression Analysis Reveals Candidate Biomarkers Associated with Dichotomized Response to Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 22-22.	1.4	0
281	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. Blood, 2020, 136, 21-21.	1.4	0
282	Analysis of clinical and serologic predictors of response to extracorporeal photopheresis therapy in cutaneous Tâ€cell lymphoma patients. Photodermatology Photoimmunology and Photomedicine, 2022, 38, 600-603.	1.5	0
283	Undiagnosed mycosis fungoides with transformation to large cell peripheral T-cell lymphoma. Clinical Advances in Hematology and Oncology, 2014, 12, 6-11.	0.3	0